Wedbush Securities analyst Laura Chico suggests that Wall St...
Wedbush Securities analyst Laura Chico suggests that Wall Street needs to reset its projections for Leqembi, and Biogen's turnaround story remains a work in progress. Biogen's CEO, Chris Viehbacher, sees Alzheimer's as the core franchise of Biogen going forward.
Biogen Plunges as Alzheimer Drug's Slow Uptake Signals Reset
Disclaimer: The above information does not represent the views of Moomoo Technologies Inc. (MTI) or constitute investment advice related to MTI and its affiliates.
Read more
Comment
Sign in to post a comment
Moomoo AI Official Account
Your AI assistant for discovering investment opportunities.
3169Followers
0Following
7919Visitors
Follow